Moderna, Inc.
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Strategic collaborations by Year
Strategic collaborations — Blackstone Life Sciences (influenza) funding recognized as contra-R&D ($M) ($M)
Moderna Strategic collaborations: $340M in FY2025, up 27.3% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Collaboration & Development Funding Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Strategic collaborations — Blackstone Life Sciences (influenza) funding recognized as contra-R&D ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 340 | +27.3% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 267 | – | Form 10-K (filed 2026-02-20) ↗ |
Breakdown
What makes up strategic collaborations
Cite this data
StockData. (2026). Moderna Strategic collaborations ($M), annual FY2024–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rd-blackstone-flu
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.